$AMTX

Earnings call transcript: Aemetis posts smaller loss in Q2 2026 as revenue misses

Aemetis Inc. reported Q2 2026 revenue of $62.7 million, up 20% year over year but below the $69.89 million forecast. The company posted an adjusted loss of 13 cents per share versus a 26-cent expected loss, with operating income improving to $5.8 million. It cited Section 45Z credit monetization and expects MVR-related cash flow.

Original reporting
Published Aug 6, 2026, 8:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AMTX
Neutral
medium confidence
Mentioned
$AMTX
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$AMTXNeutralMed
01

Why it matters

Traders should weigh the EPS and operating income improvement against the $7.19M revenue miss, ongoing liquidity constraints, and management’s reliance on credit monetization and project milestones for 2H 2026-2027 cash flow.

02

Market read

The stock’s modest pre-market gain reflects a cautious market view: profitability improved, but revenue missed and cash remains tight.

03

What to watch

Liquidity is a central constraint: $1M cash at quarter-end plus refinancing plans can dominate valuation even with improved operating income, and project execution (MVR, digesters) is a key swing factor.

Relevance 7/10Novelty 7/10Timing: post-earnings, pre-market reaction on Aug 6

Background

Aemetis’ Q2 2026 earnings call transcript centers on improved operating profitability alongside a revenue shortfall, with heavy emphasis on monetizing federal and state renewable credits.

Company-level read

Ticker impact

$AMTXNeutralMedium confidence
Context

Aemetis reported Q2 2026 adjusted EPS loss of 13 cents versus 26 cents expected, but revenue missed at $62.7M vs $69.89M.

Expected impact

Near-term trading bias is likely choppy, with upside capped until revenue consistency and liquidity improve.

Evidence & confidence

The article highlights a sharp operating income improvement and credit monetization, but also a sizable revenue shortfall, low cash, and ongoing refinancing needs.

Market effects

Reinforces that renewable fuels credits (45Z, LCFS) can materially swing earnings for small biofuel producers, increasing sensitivity to policy and credit pricing.

Highlights California ethanol and dairy RNG as key drivers, implying regional demand and pricing remain central to results.

India biodiesel allocations and potential Universal Biofuels stake sale add cross-border execution and capital-market sensitivity.

Counterpoint

The profitability inflection may be credit-driven and not yet reflected in top-line consistency, so the revenue miss could reassert downside if credit values or volumes normalize.

Key entities

  • Aemetis Inc.

    Reported Q2 2026 adjusted loss of 13 cents/share and revenue of $62.7M, plus guidance catalysts tied to MVR, LCFS, 45Z, and India biodiesel allocations.

  • Todd Waltz

    CFO quoted on Q2 revenue growth and operating income improvement.

  • Eric McAfee

    CEO quoted on multiple revenue streams per dairy RNG MMBtu and MVR’s expected natural gas reduction.

Related articles

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

$AMTXMed

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_998023.htm EXHIBIT 99.1 AEMETIS Q2'2026 EARNINGS ex_998023.htm Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemeti

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.